Overview

The CJC/IPA protocol refers to the combined use of CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF) and Ipamorelin, two peptides that stimulate growth hormone (GH) release through distinct but complementary pathways. CJC-1295 (no DAC) is a growth hormone-releasing hormone (GHRH) analog that amplifies the natural GH pulse, while Ipamorelin is a selective ghrelin receptor agonist that initiates GH release from the pituitary.

The synergy between these two peptides produces a more robust and physiologically natural GH release pattern than either peptide alone. CJC-1295 (no DAC) increases the amplitude of GH pulses by stimulating GHRH receptors, while Ipamorelin triggers the pulse itself through the ghrelin/GHS-R1a pathway. Importantly, Ipamorelin is considered one of the most selective growth hormone secretagogues, producing minimal increases in cortisol, prolactin, or appetite compared to other GH secretagogues like GHRP-6 or hexarelin.

The protocol is typically administered via subcutaneous injection, with common dosing schedules of 100–300 mcg of each peptide, 1–3 times daily, often timed around sleep and fasted states to complement the body's natural GH secretion patterns. Users and clinicians report benefits including improved body composition, enhanced recovery from exercise, improved sleep quality, and skin health. The CJC/IPA combination has become one of the most widely used peptide protocols in anti-aging and performance optimization medicine.

Mechanism of Action

Synergistic GHRH + GHRP Dual-Receptor Protocol

The CJC/IPA protocol combines CJC-1295 (no DAC) — also known as modified GRF (1-29) or MOD-GRF — with Ipamorelin, a selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. This protocol exploits the well-documented synergy between GHRH receptor and GHS-R1a receptor co-activation on pituitary somatotroph cells, where simultaneous stimulation produces GH release that is 3-10 fold greater than either peptide alone. The synergy arises from convergent intracellular signaling: CJC-1295 activates the Gs/cAMP/PKA pathway while ipamorelin activates Gq/PLC/IP3/DAG signaling, together producing supraadditive calcium mobilization and GH vesicle exocytosis (PMID: 9467534).

CJC-1295 (No DAC) — Modified GRF 1-29 Pharmacology

CJC-1295 without DAC (MOD-GRF 1-29) retains the four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) conferring DPP-IV resistance but lacks albumin conjugation, providing a plasma half-life of approximately 30 minutes. This preserves the physiological pulsatile pattern of GHRH signaling — a brief receptor activation followed by clearance — which maintains somatotroph sensitivity and avoids the receptor desensitization associated with continuous GHRH exposure from DAC-conjugated variants.

Ipamorelin — Selective GHS-R1a Agonist

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates GHS-R1a without stimulating ACTH, cortisol, or prolactin release — distinguishing it from GHRP-6 and GHRP-2 which activate multiple pituitary cell types. Ipamorelin's selectivity derives from its lack of affinity for melanocortin receptors and minimal activation of non-somatotroph GHS-R1a populations. It also suppresses somatostatin release from hypothalamic periventricular neurons, disinhibiting GH secretion (PMID: 9849822).

Protocol Rationale & Pulsatile GH Restoration

The CJC/IPA protocol is typically administered 2-3 times daily (pre-sleep and morning fasted) via subcutaneous injection to recreate physiological GH pulsatility — the diurnal pattern of high-amplitude nocturnal pulses that diminishes with aging (somatopause). By combining pulsatile GHRH with ghrelin-mimetic co-stimulation, the protocol amplifies endogenous GH pulse amplitude while preserving the interpulse nadir and negative feedback architecture of the GH-IGF-1 axis.

Reconstitution Calculator

Safety Profile

Safety Profile: CJC/IPA Protocol (CJC-1295 no DAC + Ipamorelin)

Common Side Effects

• Injection site reactions: transient redness, swelling, and mild pain at subcutaneous injection sites
• Mild headache, especially during the first week of administration
• Transient facial and trunk flushing lasting 5–20 minutes post-injection
• Increased appetite (ghrelin receptor activation by ipamorelin, though less than GHRP-6)
• Water retention: mild peripheral edema and temporary weight gain (1–3 lbs)
• Fatigue and drowsiness, particularly with evening dosing (GH promotes deep sleep)
• Tingling or numbness in fingers and toes (paresthesia)

Serious Adverse Effects

• Carpal tunnel syndrome: dose-dependent; caused by IGF-1–mediated tissue edema compressing the median nerve
• Insulin resistance: prolonged GH elevation antagonizes insulin signaling; fasting glucose may rise 5–15 mg/dL; particularly relevant in pre-diabetic individuals
• Joint pain and myalgia: GH-related connective tissue water retention and growth
• Potential tumor promotion: GH/IGF-1 axis activation is a known proliferative signal; contraindicated in patients with active or recent malignancy
• Cortisol suppression or elevation: GHRH/GHRP protocols may modestly alter adrenal axis; less pronounced than with GHRP-6 or hexarelin
• Note: CJC-1295 without DAC (ModGRF 1-29) has a shorter half-life (~30 minutes) vs. DAC version (~6–8 days), resulting in more physiologic pulsatile GH release and generally better tolerability

Contraindications

• Active cancer or history of hormone-sensitive malignancy
• Uncontrolled diabetes mellitus or diabetic retinopathy
• Active pituitary tumors or hyperpituitarism
• Pregnancy or lactation
• Under 25 years of age (risk of abnormal growth plate stimulation)
• Severe hepatic or renal impairment

Drug Interactions

• Insulin and oral hypoglycemics: GH-mediated insulin resistance may require medication dose adjustment; monitor blood glucose closely
• Glucocorticoids (prednisone, hydrocortisone): suppress endogenous GH release and may reduce protocol efficacy; GH also alters cortisol clearance
• Thyroid hormones: GH accelerates T4-to-T3 conversion; may unmask subclinical hypothyroidism or alter levothyroxine requirements
• Other GH secretagogues (MK-677, GHRP-2, sermorelin): stacking increases cumulative GH/IGF-1 burden and side effect risk
• Somatostatin / octreotide: directly inhibits GHRH action, negating protocol effects

Population-Specific Considerations

• Regulatory status: neither CJC-1295 (no DAC) nor ipamorelin is FDA-approved; all use is experimental/off-label; sourcing quality varies dramatically
• Anti-aging population (40–65): most common user demographic; benefits include improved sleep, body composition, and recovery; risks are generally manageable with proper monitoring
• Athletes: both peptides are WADA-prohibited; detectable via GH biomarker testing
• Women: may require lower doses (50–100 mcg each, 1–2x daily); increased sensitivity to water retention and joint symptoms
• Monitoring protocol: baseline and periodic (every 8–12 weeks) assessment of IGF-1, fasting glucose, HbA1c, insulin, thyroid panel (TSH, free T3, free T4), and prolactin
• Cycling: typically administered 5 days on / 2 days off or in 8–12 week cycles with 4-week breaks to prevent receptor desensitization and maintain hypothalamic-pituitary sensitivity

Pharmacokinetic Profile